Clinical Trial Update: Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial comparing carboplatin-paclitaxel-bevacizumab with alternative regimens including rucaparib, selected by HRD status, in advanced ovarian, prima…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Carboplatin-Paclitaxel-Bevacizumab-Rucaparib
• Carboplatin-Paclitaxel-Rucaparib-Bevacizumab
• carboplatin-paclitaxel-bevacizumab

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Advanced (Stage IIIB-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 1, Phase 2 | Status: UNKNOWN